

19 Nov 2021 | News

QUOTED. Renee Ryan.

by

Cala Health's FDA-cleared Cala Trio wearable for treating essential tremor is currently being tested in Parkinson's disease patients, with a \$20bn market on the line. Company CEO Renee Ryan discussed the advantages of the treatment.

“The key advantage for us again is that patients have full control over their device. It's reversible, you can turn it off and we don't have side-effects.” – Renee Ryan, CEO, Cala Health

- Find out more: [Cala Health Hopes To Jolt Essential Tremor Market With Wrist-Worn Non-Invasive Stimulation](#)

[Click here](#) for a free trial of *Medtech Insight*